Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Translocation t(1;19) is related to low cellular drug resistance in childhood acute lymphoblastic leukaemia

Leukemia volume 19, pages 165–169 (2005)Cite this article

TO THE EDITOR

Cytogenetic and molecular analyses of leukaemic cells have identified therapeutically important subgroups of childhood acute lymphoblastic leukaemia (ALL). One of the most frequently observed translocations is t(1;19)(q23;p13), which occurs in 2–5% of children with B-lineage ALL.1 Cytogenetically, two forms are found, one balanced t(1;19)(q23;p13) and one unbalanced der(19) t(1;19)(q23;p13), both giving rise to the E2A/PBX1 fusion gene. The resulting aberrant protein product appears to have oncogenic potential by affecting cell differentiation (for a review see Hunger2).

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Rubnitz JE, Pui CH . Recent advances in the treatment and understanding of childhood acute lymphoblastic leukaemia. Cancer Treat Rev 2003; 29: 31–44.

    Article  Google Scholar 

  2. Hunger SP . Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: clinical features and molecular pathogenesis. Blood 1996; 87: 1211–1224.

    CAS  PubMed  Google Scholar 

  3. Crist WM, Carroll AJ, Shuster JJ, Behm FG, Whitehead M, Vietti TJ et al. Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13): a Pediatric Oncology Group study. Blood 1990; 76: 117–122.

    CAS  PubMed  Google Scholar 

  4. Uckun FM, Sensel MG, Sather HN, Gaynon PS, Arthur DC, Lange BJ et al. Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: a report from the Children's Cancer Group. J Clin Oncol 1998; 16: 527–535.

    Article  CAS  Google Scholar 

  5. Pui CH, Raimondi SC, Hancock ML, Rivera GK, Ribeiro RC, Mahmoud HH et al. Immunologic, cytogenetic, and clinical characterization of childhood acute lymphoblastic leukemia with the t(1;19) (q23; p13) or its derivative. J Clin Oncol 1994; 12: 2601–2606.

    Article  CAS  Google Scholar 

  6. Rivera GK, Raimondi SC, Hancock ML, Behm FG, Pui CH, Abromowitch M et al. Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet 1991; 337: 61–66.

    Article  CAS  Google Scholar 

  7. Chessells JM, Harrison G, Lilleyman JS, Bailey CC, Richards SM . Continuing (maintenance) therapy in lymphoblastic leukaemia: lessons from MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia. Br J Haematol 1997; 98: 945–951.

    Article  CAS  Google Scholar 

  8. Gustafsson G, Schmiegelow K, Forestier E, Clausen N, Glomstein A, Jonmundsson G et al. Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO). Leukemia 2000; 14: 2267–2275.

    Article  CAS  Google Scholar 

  9. Frost BM, Nygren P, Gustafsson G, Forestier E, Jonsson OG, Kanerva J et al. Increased in vitro cellular drug resistance is related to poor outcome in high-risk childhood acute lymphoblastic leukaemia. Br J Haematol 2003; 122: 376–385.

    Article  CAS  Google Scholar 

  10. Forestier E, Johansson B, Gustafsson G, Borgstrom G, Kerndrup G, Johannsson J et al. Prognostic impact of karyotypic findings in childhood acute lymphoblastic leukaemia: a Nordic series comparing two treatment periods. For the Nordic Society of Paediatric Haematology and Oncology (NOPHO) Leukaemia Cytogenetic Study Group. Br J Haematol 2000; 110: 147–153.

    Article  CAS  Google Scholar 

  11. Nygren P, Kristensen J, Jonsson B, Sundstrom C, Lonnerholm G, Kreuger A et al. Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphoblastic leukemia. Leukemia 1992; 6: 1121–1128.

    CAS  PubMed  Google Scholar 

  12. Frost BM, Forestier E, Gustafsson G, Nygren P, Hellebostad M, Jonsson OG et al. Translocation t(12;21) is related to in vitro cellular drug sensitivity to doxorubicin and etoposide in childhood acute lymphoblastic leukemia. Blood 2004; 104: 2452–2457.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Ms Anna-Karin Lannergård, Ms Christina Leek, and Ms Lena Lenhammar for skilful technical assistance, and all colleagues in the Nordic Society of Paediatric Haematology and Oncology who provided the patient samples. The Lions Cancer Research Fund, the Swedish Child Cancer Foundation, and the Nordic Cancer Union supported this work financially.

Author information

Authors and Affiliations

  1. Department of Women's and Children's Health, University Children's Hospital, Uppsala, Sweden

    B M Frost & G Lönnerholm

  2. Department of Clinical Sciences, Pediatrics, University of Umeå, Sweden

    E Forestier

  3. Department of Pediatric Oncology, Karolinska Institute, Stockholm, Sweden

    G Gustafsson

  4. Department of Oncology, Radiology and Clinical Immunology, University Hospital, Uppsala, Sweden

    P Nygren

  5. Department of Pediatrics, Ullevål University Hospital, Oslo, Norway

    M Hellebostad

  6. Department of Pediatrics, Landspitali University Hospital, Reykjavik, Iceland

    G Jonmundsson

  7. Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland

    J Kanerva

  8. Pediatric Clinic II, Rigshospitalet, Copenhagen, Denmark

    K Schmiegelow

  9. Department of Medical Sciences, Section of Pharmacology, University Hospital, Uppsala, Sweden

    R Larsson

Authors
  1. B M Frost
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E Forestier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G Gustafsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P Nygren
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Hellebostad
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G Jonmundsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J Kanerva
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K Schmiegelow
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R Larsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. G Lönnerholm
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

On behalf of the Nordic Society for Paediatric Haematology and Oncology

Corresponding author

Correspondence to B M Frost.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Frost, B., Forestier, E., Gustafsson, G. et al. Translocation t(1;19) is related to low cellular drug resistance in childhood acute lymphoblastic leukaemia. Leukemia 19, 165–169 (2005). https://doi.org/10.1038/sj.leu.2403540

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403540

This article is cited by

Search

Advanced search

Quick links